BHADHURI, A.; INSINGA, R.; GUGGISBERG, P.; PANJE, C.; SCHWENKGLENKS, M. Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland. Swiss Medical Weekly, [S. l.], v. 149, n. 5152, p. w20170, 2019. DOI: 10.4414/smw.2019.20170. Disponível em: https://smw.ch/index.php/smw/article/view/2711. Acesso em: 21 may. 2024.